ArticleVisual neuroscience2017
Intravitreally-administered dopamine D2-like (and D4), but not D1-like, receptor agonists reduce form-deprivation myopia in tree shrews.
Article in Visual neuroscience, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 39 citations in OpenAlex.
- Navigating the Core Challenges of Atropine Therapy in Myopia: A Mechanistic and Clinical Analysis of Dose, Response, and Durability.Journal of ophthalmology · 2026Review
- Amine-responsive Rhodopsin-like GPCRs in ocular pathology: mechanistic associations, candidate biomarkers, and therapeutic potential.Frontiers in physiology · 2026Review
- IMI: The Role of Light in Refractive Development and Myopia: Evidence from Animal and Human Studies.Investigative ophthalmology & visual science · 2025Review
- Methylphenidate Inhibits the Development of Myopia by Altering Dopamine and Norepinephrine Reuptake.Investigative ophthalmology & visual science · 2025Article
- Topical Dopamine Application on Form-Deprivation Myopia in Rabbits.Life (Basel, Switzerland) · 2025Article
- Rapid myopization of the fellow eye in anisometropic amblyopia treated with 1% atropine: a case report.BMC ophthalmology · 2025Article
- New Advances in Drug Research for Myopia Control in Adolescents.Current drug targets · 2025Review
- Pupillary Light Reflex Reveals Melanopsin System Alteration in the Background of Myopia-26, the Female Limited Form of Early-Onset High Myopia.Investigative ophthalmology & visual science · 2024Article
- Retardation of myopia by atropine regimes.International journal of ophthalmology · 2024Review
- Mice LackingInternational journal of molecular sciences · 2022Article
- Candidate pathways for retina to scleral signaling in refractive eye growth.Experimental eye research · 2022Review
- The Role of Atropine in Preventing Myopia Progression: An Update.Pharmaceutics · 2022Review
- Retinal Dopamine D2 Receptors Participate in the Development of Myopia in Mice.Investigative ophthalmology & visual science · 2022Article
- Ocular Penetrance and Safety of the Dopaminergic Prodrug Etilevodopa.Translational vision science & technology · 2021Article
- Coadministration With Carbidopa Enhances the Antimyopic Effects of Levodopa in Chickens.Investigative ophthalmology & visual science · 2021Article
- Form-Deprivation and Lens-Induced Myopia Are Similarly Affected by Pharmacological Manipulation of the Dopaminergic System in Chicks.Investigative ophthalmology & visual science · 2020Article
- Levodopa inhibits the development of lens-induced myopia in chicks.Scientific reports · 2020Article
- Effectiveness and safety of topical levodopa in a chick model of myopia.Scientific reports · 2019Article
- IMI - Report on Experimental Models of Emmetropization and Myopia.Investigative ophthalmology & visual science · 2019Review
- Prevention of Progression in Myopia: A Systematic Review.Diseases (Basel, Switzerland) · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
We examined the effect of intravitreal injections of D1-like and D2-like dopamine receptor agonists and antagonists and D4 receptor drugs on form-deprivation myopia (FDM) in tree shrews, mammals closely related to primates. In eleven groups (n = 7 per group), we measured the amount of FDM produced by monocular form deprivation (FD) over an 11-day treatment period. The untreated fellow eye served as a control. Animals also received daily 5 µL intravitreal injections in the FD eye. The reference group received 0.85% NaCl vehicle. Four groups received a higher, or lower, dose of a D1-like receptor agonist (SKF38393) or antagonist (SCH23390). Four groups received a higher, or lower, dose of a D2-like receptor agonist (quinpirole) or antagonist (spiperone). Two groups received the D4 receptor agonist (PD168077) or antagonist (PD168568). Refractions were measured daily; axial component dimensions were measured on day 1 (before treatment) and day 12. We found that in groups receiving the D1-like receptor agonist or antagonist, the development of FDM and altered ocular component dimensions did not differ from the NaCl group. Groups receiving the D2-like receptor agonist or antagonist at the higher dose developed significantly less FDM and had shorter vitreous chambers than the NaCl group. The D4 receptor agonist, but not the antagonist, was nearly as effective as the D2-like agonist in reducing FDM. Thus, using intravitreally-administered agents, we did not find evidence supporting a role for the D1-like receptor pathway in reducing FDM in tree shrews. The reduction of FDM by the dopamine D2-like agonist supported a role for the D2-like receptor pathway in the control of FDM. The reduction of FDM by the D4 receptor agonist, but not the D4 antagonist, suggests an important role for activation of the dopamine D4 receptor in the control of axial elongation and refractive development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.